Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 14/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23902307 | 0.94 | NISCH (0.60) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL23901785 | 0.91 | NISCH (0.58) | NISCHTOP2ATOP2B | |
| SCHEMBL23902159 | 0.87 | NISCH (0.52) | NISCH | |
| SCHEMBL23902200 | 0.84 | NISCH (0.68) | NISCHLMNARECQLMAOBMAOA | |
| Hydrochloric Acid SCHEMBL10928251 | 0.84 | NISCH (0.67) | NISCHLMNARECQLTOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL23880726 | 0.83 | NISCH (0.66) | NISCHLMNARECQLMAOBTOP2A | |
| SCHEMBL23902226 | 0.82 | NISCH (0.60) | NISCHLMNARECQLTOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL23235807 | 0.81 | NISCH (0.58) | NISCHLMNARECQLMAOBTOP2A | |
| SCHEMBL4706553 | 0.80 | NISCH (0.71) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL3532945 | 0.80 | NISCH (0.71) | NISCHLMNARECQLTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | NISCH 24/4885LMNA 2726/4885RECQL 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.